[HTML][HTML] Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5–11 years and adolescents …
AL Fowlkes - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
AL Fowlkes
MMWR. Morbidity and mortality weekly report, 2022•cdc.govEffectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2
Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT
Cohort, July 2021–February 2022 | MMWR Skip directly to site content Skip directly to page
options Skip directly to AZ link Centers for Disease Control and Prevention. CDC twenty four
seven. Saving Lives, Protecting People Search Submit Morbidity and Mortality Weekly Report
(MMWR) Facebook Twitter LinkedIn Syndicate Effectiveness of 2-Dose BNT162b2 (Pfizer …
Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT
Cohort, July 2021–February 2022 | MMWR Skip directly to site content Skip directly to page
options Skip directly to AZ link Centers for Disease Control and Prevention. CDC twenty four
seven. Saving Lives, Protecting People Search Submit Morbidity and Mortality Weekly Report
(MMWR) Facebook Twitter LinkedIn Syndicate Effectiveness of 2-Dose BNT162b2 (Pfizer …
Receipt of 2 doses of Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing infection with the SARS-CoV-2 B. 1.617. 2 (Delta) variant in persons aged≥ 12 years.
cdc.gov